This week, we will discuss SODaBIC trial: with ICU acidosis driven by multiple overlapping mechanisms, is bicarbonate infusion supported by robust evidence, or does it persist mainly out of habit rather than physiology?
FIND-CKD extends finerenone beyond diabetic kidney disease, showing slower eGFR decline and sustained albuminuria reduction in non-diabetic CKD. While the benefits are modest and cardiovascular effects remain uncertain, the trial opens the door to broader use of nsMRAs and raises important questions about combination therapy with SGLT2 inhibitors.
Can rivaroxaban improve cardiovascular outcomes in patients with advanced CKD.? Although vascular inflammation and thrombosis are at the heart of CV damage, anticoagulants have not previously shown benefits in CVD patients.
This week, NephJC will discuss whether obinutuzumab is ready to outperform tacrolimus in primary membranous nephropathy
Our NephJC NOSTONE editorial in Kidney Medicine is live. Great work from Renz Palisan, Nikita Pawar, and Rasha Alawieh; supported by Swap and Jade.
Read it here.
Thiazides to prevent rolling stones - the Ten Tweet summary of NOSTONE is here.
Welcome to #TenTweetNephJC - we’re again covering a practice changing trial, but unfortunately one that shows a treatment we’ve prescribed for decades for kidney stone prevention ain’t doing a huge amount....🧵 pic.twitter.com/j23gn9grw1
— Nephrology Journal Club (@NephJC) May 3, 2023
Check out the crisp VA on NOSTONE trial by Renz Pasilan
